HIGH

Carbamazepine Extended-Release 400 mg Tablets Recalled for Failed Dissolution Specifications (D-0675

FDA recalls Carbamazepine Extended-Release Tablets, 400 mg, distributed nationwide by American Health Packaging. The recall cites failed dissolution specifications and class II classification. Consumers should stop using and contact healthcare providers for guidance.

Quick Facts at a Glance

Recall Date
September 15, 2025
Hazard Level
HIGH
Brands
Carbamazepine, American Health Packaging
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT, PETS

Hazard Information

Failed Dissolution Specifications.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Amerisource Health Services LLC or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Carbamazepine extended-release tablets are used to treat seizures and nerve pain. This recall involves 360 cartons distributed nationwide.

Why This Is Dangerous

Failure to dissolve as specified can alter drug release and absorption, potentially impacting effectiveness and safety.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

The recall may affect adherence to prescribed therapy and require medical guidance for safe continuation.

Practical Guidance

How to identify if yours is affected

  1. Check carton NDC 60687-594-21
  2. Check Individual Dose NDC 60687-594-11
  3. Inspect Lot #1024078 and Exp. Date 08/31/2026
  4. Confirm 30 tablets per carton (3x10 cards)
  5. Confirm 360 cartons distributed nationwide

Where to find product info

On the carton and patient information leaflets; FDA enforcement page for D-0675-2025

What timeline to expect

Refund or replacement timelines will be provided in recall communications by Amerisource Health Services LLC and pharmacies

If the manufacturer is unresponsive

  • Document all communications
  • File a consumer complaint with the FDA recall search
  • Consult pharmacist for alternatives

How to prevent similar issues

  • Verify NDC and lot numbers before dispensing new prescriptions
  • Ask pharmacists about dissolution specifications and stability
  • Use approved pharmacies and verify shelf life at receipt

Documentation advice

Keep the recall notice, receipts, and any correspondence with healthcare providers or pharmacies

Product Details

Carbamazepine Extended-Release Tablets, USP 400 mg. 30 tablets per carton (3x10 unit dose cards). Rx Only. Distributor: American Health Packaging, Columbus, OH 43217. Carton NDC 60687-594-21; Individual Dose NDC 60687-594-11. Quantity: 360 cartons. Lot #: 1024078. Exp. Date: 08/31/2026. Sold nationwide in the USA. Generic name CARBAMAZEPINE; Brand CARBAMAZEPINE.

Reported Incidents

No injuries or incidents have been reported in the provided data.

Key Facts

  • 360 cartons recalled
  • Carton NDC 60687-594-21
  • Individual Dose NDC 60687-594-11
  • Lot #1024078
  • Exp. Date 08/31/2026
  • High-risk drug category (Rx only)

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANTPETS
Injury Types
LACERATIONOTHER

Product Classification

Product Details

Model Numbers
Lot #: 1024078
Exp. Date 08/31/2026
UPC Codes
60687-583
60687-594
60687-583-11
+3 more
Affected States
ALL
Report Date
October 8, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more